ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,767.50
0.10%
S&P ASX All Technology
3,137.90
0.55%
Brent Oil
84.85
-0.66%
US Dollar vs AUD
1.49566
-0.53%
Bitcoin
60,198.70
-2.29%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Summit Therapeutics Inc (SMMT)

  7. Summit Therapeutics Inc (SMMT) News

SMMT

Summit Therapeutics (SMMT)

Summit Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SMMT
DateTimeSourceHeadlineSymbolCompany
28/06/202406:15Business WireSummit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
19/06/202407:14Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SMMTSummit Therapeutics Inc
18/06/202407:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
14/06/202404:03Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SMMTSummit Therapeutics Inc
03/06/202420:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
03/06/202420:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
03/06/202419:30Business WireSummit Raises $200 Million; Also Expands License Territories for IvonescimabNASDAQ:SMMTSummit Therapeutics Inc
01/06/202422:00Business WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
01/06/202409:00Business Wire Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus ChemotherapyNASDAQ:SMMTSummit Therapeutics Inc
31/05/202408:00Business WireSummit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SMMTSummit Therapeutics Inc
31/05/202406:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
31/05/202404:29Business WireIvonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in ChinaNASDAQ:SMMTSummit Therapeutics Inc
24/05/202422:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/05/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
13/05/202421:48Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SMMTSummit Therapeutics Inc
01/05/202421:00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024NASDAQ:SMMTSummit Therapeutics Inc
25/04/202406:30Business WireSummit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024NASDAQ:SMMTSummit Therapeutics Inc
12/04/202406:30Business WireSummit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of DirectorsNASDAQ:SMMTSummit Therapeutics Inc
10/04/202421:00Business WireSummit Therapeutics to Present at the Stifel 2024 Targeted Oncology ForumNASDAQ:SMMTSummit Therapeutics Inc
22/03/202422:00Business WirePromising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
14/03/202422:00Business WireIntracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024NASDAQ:SMMTSummit Therapeutics Inc
06/03/202408:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
05/03/202423:00Business WireSummit Therapeutics to Present at the Barclays 26th Annual Global Healthcare ConferenceNASDAQ:SMMTSummit Therapeutics Inc
21/02/202400:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
20/02/202423:55Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SMMTSummit Therapeutics Inc
20/02/202423:32Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:SMMTSummit Therapeutics Inc
20/02/202423:00Business WireSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023NASDAQ:SMMTSummit Therapeutics Inc
16/02/202409:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SMMTSummit Therapeutics Inc
15/02/202408:35Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:SMMTSummit Therapeutics Inc
15/02/202402:29Business WireSummit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024NASDAQ:SMMTSummit Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SMMT

Your Recent History

USOTC
FXGDF
Felix Gold (PK)
USOTC
TEMPF
Persol (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved